TuHURA Biosciences, Inc. (HURA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HURA SEC filings page.
TuHURA Biosciences, Inc. (HURA) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
TuHURA remains a development-stage business whose expanding research program is consuming cash faster than reported financing replenishes it.
From FY2024 to FY2025, research and development spending rose from$13.3M to$20.5M while operating cash use widened from$14.7M to$27.6M . That pairing indicates the larger loss of cash was mainly tied to intensifying development activity, not investment in a revenue-producing operating base.
FY2025 reported financing inflow of
Free cash flow of
Financial Health Signals
TuHURA Biosciences, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
TuHURA Biosciences, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
TuHURA Biosciences, Inc. reported a net loss of $31.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
TuHURA Biosciences, Inc. reported -$9.2M in net income in Q2 2026. This represents an increase of 3.2% from the same quarter a year earlier. Against the prior quarter it is down 22.4%.
TuHURA Biosciences, Inc. earned -$0.14 per diluted share (EPS) in Q2 2026. This represents an increase of 33.3% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
TuHURA Biosciences, Inc. recorded an outflow of $8.8M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 40.2% from the same quarter a year earlier. Against the prior quarter it is down 96.6%.
TuHURA Biosciences, Inc. held $996K in cash against $3.6M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
TuHURA Biosciences, Inc.'s ROE was -49.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 17.3 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
TuHURA Biosciences, Inc. invested $6.6M in research and development in Q2 2026. This represents an increase of 34.4% from the same quarter a year earlier. Against the prior quarter it is up 26.5%.
TuHURA Biosciences, Inc. invested $137K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 2363.2% from the same quarter a year earlier. Against the prior quarter it is up 180.4%.
Not reported for Q2 2026.
HURA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| R&D Expenses | $6.6M+34.4% | $5.2M+14.2% | N/A | $5.0M+68.6% | $4.9M+74.5% | $4.6M+27.7% | N/A | $2.9M+58.5% |
| SG&A Expenses | $2.1M+15.1% | $2.3M+13.9% | N/A | $1.8M+124.8% | $1.9M+134.0% | $2.0M+98.3% | N/A | $783K-29.0% |
| Interest Expense | $468K | $28K | N/A | $17K-99.2% | $0-100.0% | N/A | N/A | $2.0M |
| Net Income | -$9.2M+3.2% | -$7.5M-13.1% | N/A | -$7.1M-27.3% | -$9.5M-80.9% | -$6.7M-37.6% | N/A | -$5.6M-88.4% |
| EPS (Basic) | -$0.14+33.3% | -$0.13+13.3% | -$0.13-181.3% | -$0.14+74.1% | -$0.21+51.2% | -$0.15+62.5% | $0.16+166.7% | -$0.54+99.2% |
| EPS (Diluted) | -$0.14+33.3% | -$0.13+13.3% | -$0.13-181.3% | -$0.14 | -$0.21 | -$0.15 | $0.16 | -$0.54 |
| Diluted Shares (Avg) | 64M+43.6% | 60M+38.3% | N/A | 51M | 45M | 43M | N/A | 12M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Operating Income, EBITDA, Income Tax.
HURA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.7M-8.3% | $29.7M+102.9% | $27.4M+37.0% | $25.7M+520.7% | $34.6M+458.2% | $14.6M+96.6% | $20.0M+357.8% | $4.1M+180.3% |
| Current Assets | $1.7M-86.8% | $7.0M-51.3% | $4.6M-76.4% | $3.5M+0.6% | $12.5M+126.8% | $14.3M+112.1% | $19.6M+371.5% | $3.5M+344.8% |
| Cash & Equivalents | $996K-88.3% | $6.3M+1.3% | $3.6M-71.4% | $2.7M-10.7% | $8.5M+73.4% | $6.2M-2.1% | $12.7M+245.3% | $3.0M+1298.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $10.7M-20.8% | $10.7M | $10.7M | $13.6M | $13.6M | N/A | N/A | N/A |
| Total Liabilities | $13.2M-12.7% | $6.5M+36.2% | $6.4M+19.5% | $8.9M+29.1% | $15.2M+15.3% | $4.8M-64.6% | $5.4M-9.3% | $6.9M+97.2% |
| Current Liabilities | $9.3M-39.0% | $6.1M+26.9% | $5.9M+11.1% | $8.8M+291.4% | $15.2M+571.6% | $4.8M+256.6% | $5.3M+48.2% | $2.3M-32.3% |
| Non-Current Liabilities | $4.0M | $448K | $502K+1074.6% | $85K-98.2% | $0-100.0% | $0-100.0% | $43K-98.2% | $4.7M+2684.6% |
| Long-Term Debt | $3.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $18.5M-4.9% | $23.2M+135.3% | $20.9M+43.4% | $16.8M+706.3% | $19.4M+379.5% | $9.9M+262.5% | $14.6M+1036.3% | -$2.8M-36.6% |
| Retained Earnings | -$157.9M-24.1% | -$148.7M-26.3% | -$141.2M-27.1% | -$134.4M+17.1% | -$127.3M+20.4% | -$117.8M+25.2% | -$111.1M-25.6% | -$162.1M-4.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
HURA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.6M-38.2% | -$4.4M+6.9% | -$5.6M-113.7% | -$11.1M-486.9% | -$6.2M-23.3% | -$4.7M-23.6% | -$2.6M-22.8% | -$1.9M-43.4% |
| Depreciation & Amortization | $28K+100.0% | $23K+67.0% | $23K+27.8% | $21K-27.6% | $14K-60.0% | $14K-59.0% | $18K+17.6% | $29K+93.3% |
| Stock-Based Compensation | N/A | $2.8M+96.3% | N/A | N/A | N/A | $1.4M+325.8% | N/A | $98K-38.8% |
| Capital Expenditures | $137K+2363.2% | $49K+14.5% | $28K+30.1% | $0 | $6K | $43K | $21K | $0 |
| Free Cash Flow | -$8.8M-40.2% | -$4.5M+6.7% | -$5.6M-113.0% | -$11.1M-486.9% | -$6.3M | -$4.8M | -$2.6M | -$1.9M |
| Investing Cash Flow | -$137K+12.5% | -$49K+95.8% | -$28K+96.6% | $0+100.0% | -$156K | -$1.2M | -$824K | -$5.2M |
| Financing Cash Flow | $3.5M-60.1% | $7.1M+1403.2% | $6.5M+285.1% | $5.3M-66.4% | $8.7M-32.8% | -$548K-111.8% | -$3.5M-236.3% | $15.7M+785378.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
HURA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -49.9%-0.9pp | -32.5%+35.1pp | N/A | -42.3% | -49.0% | -67.6% | N/A | N/A |
| Return on Assets | -29.0%-1.5pp | -25.4%+20.2pp | N/A | -27.6%+107.1pp | -27.5%+57.4pp | -45.5%+19.5pp | N/A | -134.8%+65.8pp |
| Current Ratio | 0.18-0.6x | 1.15-1.8x | 0.78-2.9x | 0.40-1.1x | 0.83-1.6x | 3.00-2.0x | 3.68+2.5x | 1.54+1.3x |
| Debt-to-Equity | 0.19-0.6x | 0.28-0.2x | 0.31-0.1x | 0.53 | 0.78 | 0.49 | 0.37 | N/A |
| Asset Turnover | N/A | 0.000.0x | N/A | N/A | N/A | 0.000.0x | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. HURA | FY2025 | $0 | -$31.0M | N/A | $121.7M | — |
| IO Biotech, Inc. IOBT | FY2025 | N/A | -$95.5M | N/A | $3.5M | — |
| Oncolytics Biotech, Inc. ONCY | FY2025 | N/A | -$28.8M | N/A | $80.5M | — |
| Pyxis Oncology, Inc. PYXS | FY2025 | $13.9M | -$79.6M | N/A | $178.5M | 56/100 |
| Avalo Therapeutics, Inc. AVTX | FY2025 | $59K | -$78.3M | N/A | $803.9M | — |
| Skye Bioscience, Inc. SKYE | FY2025 | N/A | -$55.9M | N/A | $7.4M | — |
Where TuHURA Biosciences, Inc. Ranks
Frequently Asked Questions
What is TuHURA Biosciences, Inc.'s annual revenue?
TuHURA Biosciences, Inc. (HURA) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is TuHURA Biosciences, Inc. profitable?
No, TuHURA Biosciences, Inc. (HURA) reported a net income of -$31.0M in fiscal year 2025.
What is TuHURA Biosciences, Inc.'s return on equity (ROE)?
TuHURA Biosciences, Inc. (HURA) has a return on equity of -148.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is TuHURA Biosciences, Inc.'s free cash flow?
TuHURA Biosciences, Inc. (HURA) recorded an outflow of $27.7M in free cash flow during fiscal year 2025. This represents a -87.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is TuHURA Biosciences, Inc.'s operating cash flow?
TuHURA Biosciences, Inc. (HURA) recorded an outflow of $27.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are TuHURA Biosciences, Inc.'s total assets?
TuHURA Biosciences, Inc. (HURA) had $27.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are TuHURA Biosciences, Inc.'s capital expenditures?
TuHURA Biosciences, Inc. (HURA) invested $76K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does TuHURA Biosciences, Inc. spend on research and development?
TuHURA Biosciences, Inc. (HURA) invested $20.5M in research and development during fiscal year 2025.
What is TuHURA Biosciences, Inc.'s current ratio?
TuHURA Biosciences, Inc. (HURA) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is TuHURA Biosciences, Inc.'s debt-to-equity ratio?
TuHURA Biosciences, Inc. (HURA) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is TuHURA Biosciences, Inc.'s return on assets (ROA)?
TuHURA Biosciences, Inc. (HURA) had a return on assets of -113.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is TuHURA Biosciences, Inc.'s P/E ratio?
TuHURA Biosciences, Inc. (HURA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $121.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is TuHURA Biosciences, Inc.'s price-to-sales ratio?
TuHURA Biosciences, Inc. (HURA) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $121.7M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does TuHURA Biosciences, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, TuHURA Biosciences, Inc. (HURA) held $3.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.6M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is TuHURA Biosciences, Inc.'s Piotroski F-Score?
TuHURA Biosciences, Inc. (HURA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are TuHURA Biosciences, Inc.'s earnings high quality?
TuHURA Biosciences, Inc. (HURA) reported a net loss of $31.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.